ArticleRMD open2026
Sustaining remission in rheumatoid arthritis: the role of clinical deep remission and its implications for drug tapering.
Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWhile sustained remission is the treatment goal for rheumatoid arthritis (RA), its long-term remission remains challenging. This real-world study aimed to assess the role of clinical deep remission (CliDR) in sustained remission and the risk of relapse, as well as its interaction with drug tapering.
methodsOf the 541 patients enrolled in the cohort, 145 who achieved a Disease Activity Score in 28 joints using C reactive protein (CRP) remission with 5 years of follow-up after remission were included in this study. Participants were stratified by CliDR status (defined as no tender/swollen joints with normal CRP/erythrocyte sedimentation rate). Kaplan-Meier analysis was used to compare sustained remission rates. Multivariable Cox regression with time-dependent covariates was performed to identify independent predictors and to assess the interaction between CliDR and drug tapering.
resultsThe sustained remission rate declined over time but was significantly higher in the CliDR group (62.5%; 95% CI 45.3% to 77.1%) than the non-CliDR group (38.1%; 95% CI 29.6% to 47.3%) at 5 years (p=0.014). In the non-CliDR group, tapering was associated with an 8.47-fold increase in the hazard of relapse (HR=8.47, 95% CI 5.01 to 14.32, p<0.001). The interaction between group and tapering was statistically significant (HR=0.26, 95% CI 0.07 to 0.98, p=0.046), indicating that the effect of tapering on relapse risk was significantly attenuated in the CliDR group compared with the non-CliDR group.
conclusionsOur findings suggest that achieving CliDR is associated with significantly higher sustained remission rates in RA and that the safety of treatment tapering is contingent on prior achievement of CliDR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.